medicine-news-1/wyeth-pharmaceuticals-and-catalyst-biosciences-announce-agreement-to-develop-and-commercialize-factor-viia-products-50389-5/;msg90356
| We're sorry, that page (http://www.bio-medicine.org/medicine-news-1/wyeth-pharmaceuticals-and-catalyst-biosciences-announce-agreement-to-develop-and-commercialize-factor-viia-products-50389-5/;msg90356) was not found. Search medicine news 1 wyeth pharmaceuticals and catalyst biosciences announce agreement to develop and commercialize factor viia products 50389 5 ;msg90356 at Google Search medicine news 1 wyeth pharmaceuticals and catalyst biosciences announce agreement to develop and commercialize factor viia products 50389 5 ;msg90356 at Yahoo Search medicine news 1 wyeth pharmaceuticals and catalyst biosciences announce agreement to develop and commercialize factor viia products 50389 5 ;msg90356 at Msn |
Breaking Biology Technology:SciVal Spotlight Gaining Momentum Across the Globe as More Universities Seek Multidisciplinary View of Research Performance 2SciVal Spotlight Gaining Momentum Across the Globe as More Universities Seek Multidisciplinary View of Research Performance 3Eidogen-Sertanty Licenses TIP to the FDA 2Boost for Prostate Cancer Screening - Report Shows Mortality Reduction as High as 31% 2New technology could boost disease detection tests' speed and sensitivity 2
[0] SciVal Spotlight Gaining Momentum Across the Globe as More Universities Seek Multidisciplinary View of Research Performance[0] Eidogen-Sertanty Licenses TIP to the FDA[0] Boost for Prostate Cancer Screening - Report Shows Mortality Reduction as High as 31%[0] New technology could boost disease detection tests' speed and sensitivity
Breaking Medicine Technology:Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3FDA Launches Orphan Drug Workshop at KGI 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 1Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 2Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 3Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 4Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 5Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 6Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 1Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 2Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 3Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 1Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 2
| Copyright © 2003-2007 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |